Abstract Purpose of Review Optimal duration of antiplatelet therapy continues to attract
extensive debates and has been progressively adjusted in the setting of advancements in …

Dual anti-platelet therapy is prescribed in the setting of coronary heart disease for the
prevention of stent thrombosis and acute thrombotic events. The optimal duration of dual anti …

Dual antiplatelet pharmacotherapy reduces ischemic events at the cost of excess bleeding
in patients who underwent coronary stenting. The currently recommended treatment period …

Thrombus formation is a crucial event in acute coronary syndromes, 1 bypass occlusion, 2
and stent thrombosis. 3 In the coronary circulation, platelet activation is an initial event, 4 …

Determining the optimal duration of dual antiplatelet therapy (DAPT) following percutaneous
coronary intervention is a complex decision. Randomized controlled trials have shown that …

Purpose of review The optimal duration of dual antiplatelet therapy (DAPT) has been a topic
of considerable interest in recent years, as the risk of stent thrombosis has decreased with …

Percutaneous coronary intervention with stent implantation is an integral aspect of minimally
interventional cardiac procedures. The technology and techniques behind stent design and …

Background: The optimal duration of dual antiplatelet therapy (DAPT) after implantation of
newer-generation drug-eluting stents (DES) remains uncertain. Similarly, questions remain …

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is key for secondary
prevention of recurrent coronary ischemic events and stent thrombosis. For this purpose …

The optimal duration of dual antiplatelet therapy (DAPT) for stable coronary artery disease
and acute coronary syndrome is a complex decision. We review current literature on …